Syncona close to injecting funds in new prospects
(Sharecast News) - Syncona, the healthcare investor, said it was in the "final stages" of agreeing funding for two new companies, though its net asset value dipped in the past quarter.
Read moreTo deliver superior long-term capital appreciation from investments in life science businesses, leading long-only and alternative investment funds and managed accounts across multiple asset classes.
Find out MoreFri, 07th May 2021 07:31
(Sharecast News) - Syncona, the healthcare investor, said it was in the "final stages" of agreeing funding for two new companies, though its net asset value dipped in the past quarter.
Read moreLONDON (Alliance News) - FTSE 250-listed healthcare-focused investor Syncona Ltd on Monday reported on progress made by portfolio company, Nasdaq-listed Autolus Therapeutics Inc, on its has dosed
Read more(Sharecast News) - Autolus Therapeutics reported progress in clinical trials for one of its cancer treatments and said it has begun dosing patients in another trial.
Read more(Sharecast News) - Autolus Therapeutics reported progress in clinical trials for one of its cancer treatments and said it has begun dosing patients in another trial.
Read more(Sharecast News) - Life sciences investment fund Syncona saw net asset value increase in first six months of the year, as it confirmed it was on track to meet full-year investment guidance.
Read moreLONDON (Alliance News) - Syncona Ltd on Wednesday reported a more than doubled profit for the first half of its financial year, boosted by fair value gains amid a strong total return for the the a
Read moreLONDON (Alliance News) - Healthcare-focused investment firm Syncona Ltd said Friday it has invested a further USD18 million in NASDAQ-listed Nightstar Therapeutics PLC after its announced a share
Read more(Sharecast News) - Healthcare investment company Syncona updated the market on its portfolio company Nightstar Therapeutics on Monday, which reported positive proof-of-concept data from the dose escalation study in the XIRIUS trial for NSR-RPGR in XLRP patients.
Read moreLONDON (Alliance News) - FTSE 250-listed healthcare investor Syncona Ltd said on Monday its portfolio company Nightstar Therapeutics PLC reported positive results from the dose escalation study in
Read more(Sharecast News) - Healthcare company Syncona issued its quarterly update for the three months to 30 June on Thursday, reporting an increase in net assets increased to £1.28bn, or 193.1p per share, for a total return of 23%.
Read moreLONDON (Alliance News) - Healthcare investor Syncona Ltd said Thursday its net assets increased significantly in its financial first quarter, due to the strong performance and increasing size of a
Read moreLONDON (Alliance News) - FTSE 250-listed healthcare investment company Syncona Ltd said on Tuesday it has invested GBP85 million in Adeno-associated virus gene therapy company virus is a small and
Read moreLONDON (Alliance News) - Syncona Ltd on Thursday said strong results from its science portfolio and new investments resulted in an increased return for the 2018 financial year.The FTSE life
Read more(Correcting Syncona and Woodford's shareholding value in Autolus Therapeutics following the ADS offering)LONDON (Alliance News) - Healthcare investor Syncona Ltd said Friday that its an
Read moreLONDON (Alliance News) - Healthcare investor Syncona Ltd on Tuesday noted the proposed listing of American depositary shares on the Nasdaq Global Market by investee Autolus Therapeutics said the
Read more